Sector News

Medtronic announces restructuring to trim costs by billions

January 10, 2018
Life sciences

Medical-device giant Medtronic announced a multibillion-dollar restructuring program Monday that will impact an undisclosed number of employees.

The company discussed its plan at the J.P. Morgan Healthcare Conference on Monday and unveiled some details in a Securities and Exchange Commission filing. Medtronic expects the plan to result in more than $3 billion in annual gross savings by the end of its 2022 fiscal year.

The restructuring will affect an undisclosed number of employees, but Medtronic’s total employee count will hold steady, the company said in an SEC filing. Medtronic has about 9,000 employees in Minnesota and is among the state’s largest employers.

“The company expects that its overall employee base will remain relatively unchanged, as new jobs are created in new capability areas and resources are deployed to support the company’s growing market needs,” Medtronic said in a regulatory filing.

Medtronic expects to record charges of between $1.6 billion and $1.8 billion over a five-year period as a result of the restructuring, which it named “Enterprise Excellence Program.” Between 40 and 50 percent of those charges will be tied to employee-related costs, including severance expenses.

Medtronic cut an undisclosed number of jobs at its operations in Memphis over the summer, and said in August it would lay off 185 workers in Illinois after closing a distribution center. A company spokesman told MassDevice that Medtronic has more than 4,000 open positions.

Medtronic unveiled some of the program’s goals — such as improving productivity and integrating manufacturing systems — but few details.

“The program is designed to drive operating margin improvement as well as fund investment in strategic growth initiatives,” the company said in the regulatory filing.

Dublin-based Medtronic’s operational headquarters in Fridley.

By Katharine Grayson

Source: Biz Journal Minneapolis

comments closed

Related News

March 31, 2023

Eli Lilly pours $500M more into API manufacturing site under construction in Ireland

Life sciences

The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).

March 31, 2023

‘Stunning’ 4% yearly rise in R&D share has emerging biopharma dominating pipeline

Life sciences

“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”

March 31, 2023

Bayer plans to scale back women’s health R&D

Life sciences

The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.

How can we help you?

We're easy to reach